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The Use of Aerosolized Ribavirin in Respiratory Syncytial Virus Lower Respiratory
Tract Infections in Adult Immunocompromised Patients: A Systematic Review
Abstract
Introduction: Respiratory syncytial virus (RSV)–associated lower respiratory tract infection (LRTI) is a
concern in immunocompromised patients. Aerosolized ribavirin (RBV AER) is used for treatment of RSV
LRTI; however, adverse events and rising drug costs remain a challenge for patient management. The
purpose of this systematic review is to summarize the efficacy and adverse event profile of RBV AER for
the treatment of hospitalized RSV LRTI in immunocompromised adult patients. Methods: A Medline/
PubMed, Embase, Google Scholar, Clinicaltrials.gov, and Cochrane Library database search was
conducted from 1966 to January 2019 for the use of RBV AER. Search strategy: [(ribavirin OR ICN1229)
AND (“administration, oral” OR “oral” OR “administration, inhalation” OR “inhalation)] AND (“respiratory
tract infection” OR “pneumonia”). Studies were reviewed if adult patients were hospitalized,
immunocompromised, had RSV LRTI, received RBV AER, and included the outcome of mortality and/or
adverse reactions. Methodological quality was assessed using the Cochrane Collaboration GRADE
approach. Results: A total of 1787 records were identified and 15 articles met inclusion criteria:
hematopoietic stem cell transplant (HSCT)/bone marrow transplant (n = 8), other malignancy/neutropenic
(n = 2), solid organ transplant (n = 5). All of the trials are observational with a low quality rating; therefore,
a meta-analysis was not performed. The 30-day mortality in studies that contain >10 patients with HSCT,
malignancy, and transplant range from 0 to 15.4%, 6.3%, and 0 to 27%, respectively. Improved mortality
was cited in 4 studies when RBV AER started before mechanical ventilation or within 2 weeks of symptom
onset. Only 3 studies had comparative mortality data with RBV AER and RBV PO. Adverse reactions were
reported in 5 studies and included psychiatric manifestations (anxiety, depression, feeling of isolation; n =
14), wheezing/bronchospasm (n = 6), snowflakes/hail blowing in face (n = 6), and precipitation in
ventilator tubing (n = 5). Conclusion: There is a lack of high quality, comparative trials on the use of RBV
AER for the treatment of RSV LRTI in adult hospitalized immunocompromised patients. There may be a
mortality benefit when RBV AER is initiated early after diagnosis or prior to mechanical ventilation, but
requires further study. Patient isolation and psychological effects must be weighed against the benefit of
therapy.
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Abstract
Introduction: Respiratory syncytial virus (RSV) associated lower respiratory tract infection (LRTI) is a
concern in immunocompromised patients. Aerosolized ribavirin (RBV AER) is utilized for treatment of
RSV LRTI, however adverse events and rising drug costs remain a challenge for patient management.
The purpose of this systematic review is to summarize the efficacy and adverse event profile of RBV
AER for the treatment of hospitalized RSV LRTI in immunocompromised adult patients.
Methods: A Medline/PubMed, Embase, Google Scholar, Clinicaltrials.gov and Cochrane Library database
search was conducted from 1966 – January 2019 for the use of RBV AER. Search strategy: [(ribavirin OR
ICN1229) AND (“administration, oral” OR “oral” OR “administration, inhalation” OR “inhalation)]
AND (“respiratory tract infection” OR “pneumonia”). Studies were reviewed if adult patients
were hospitalized, immunocompromised, had RSV LRTI, received RBV AER, and included the outcome
of mortality and/or adverse reactions. Methodologic quality was assessed using the Cochrane
Collaboration GRADE approach.
Results: A total of 1787 records were identified and 15 articles met inclusion criteria; HSCT/BMT (n=8),
other malignancy/neutropenic (n=2), solid organ transplant (SOT) (n=5). All of the trials are
observational with a low quality rating, therefore a meta-analysis was not performed. The 30-day
mortality in studies that contain more than 10 patients with HSCT, malignancy, and transplant range from
0% to 15.4%, 6.3%, and 0% to 27% respectively. Improved mortality was cited in 4 studies when RBV
AER started before mechanical ventilation or within 2 weeks of symptom onset. Only 3 studies had
comparative mortality data with RBV AER and RBV PO. Adverse reactions were reported in 5 studies
and included psychiatric manifestations (anxiety, depression, feeling of isolation; n = 14),
wheezing/bronchospasm (n = 6), snowflakes/hail blowing in face (n = 6), and precipitation in ventilator
tubing (n = 5).

Introduction
Respiratory syncytial virus (RSV) is a member of the Paramyxoviridae family and results in
approximately 55 adult hospitalizations per 100,000 person years.1 In healthy adults, RSV typically
manifests as an upper respiratory tract infection (URTI) with patients experiencing rhinorrhea,
pharyngitis, sinusitis, and cough. Treatment consists of supportive care, typically in the outpatient setting.
In contrast, elderly and immunocompromised patients may progress from an URTI to a lower respiratory
tract infection (LRTI) with symptoms ranging from dyspnea and/or chest tightness, to acute respiratory
distress syndrome and respiratory failure. The availability of rapid diagnostic tests, including the
multiplex polymerase chain reaction (PCR) test, has increased the identification of RSV as a source of
pulmonary infections.2
Treatment of RSV may be necessary in patients with impaired cellular immunity, since the ability
to contain and eradicate RSV is reduced. Severely immunocompromised populations such as bone
marrow transplant recipients (BMT), hematopoietic stem cell transplant recipients (HSCT), neutropenic
patients, solid organ transplant recipients (SOT), and patients with human immunodeficiency virus (HIV)
have a risk of mortality from RSV as high as 80%.3 In addition, RSV infections in lung transplant
recipients may increase the risk of chronic rejection.4 Despite the high mortality and morbidity associated
with RSV infections in immunocompromised patients, there remains a lack of prospective, randomized
trials to help guide clinicians on appropriate management of LRTI in hospitalized adults.
Current treatment options for RSV LRTI include aerosolized or oral ribavirin (RBV) in
combination with palivizumab (PZB), corticosteroids, and/or intravenous immunoglobulin (IVIG).
Aerosolized ribavirin (RBV AER) was approved by the Food and Drug Administration (FDA) in 1985 for
the treatment of RSV in hospitalized pediatric patients.5-6 Therapy may only be administered via the
small particle aerosol generator which produces particles in the range of 1.0 to 1.3 µm to ensure adequate
concentrations in the lower respiratory tract.7 Safety concerns of RBV AER include bronchospasm and
dyspnea; furthermore, healthcare workers and visitors must be aware of potential teratogenic effects.
Additionally, cost of RBV AER has risen dramatically since FDA approval, with most recent estimates of

an average wholesale price (AWP) of nearly $120,000 U.S. dollars (USD) for four-6g vials and $10,000
less for the generic.8
Drug administration barriers, including high acquisition cost, and lack of controlled trials has
made use of RBV AER for treatment of RSV LRTI in hospitalized adults with immunocompromising
conditions challenging.9 The decision to initiate therapy is even more difficult when
immunocompromised patients present with RSV LRTI to a non-transplant community hospitals which
might not have established protocols like transplant or oncology centers. The purpose of this systematic
review is to summarize the efficacy and adverse drug event (ADE) profile of RBV AER for the treatment
of RSV LRTI in adult immunocompromised patients.

Methods
Study design and data source
This systematic review was designed to examine the outcomes reported in comparative clinical trials and
cohorts for the use of RBV AER in the treatment of LRTI caused by RSV in hospitalized
immunocompromised adults. A systematic search of the literature was conducted in the following
databases: Medline via PubMed (1966 – May 2016) date last search 1/8/2019, Embase (<1966 – May
2016), Clinicaltrials.gov, The Cochrane Library (no date limit performed on) and Google Scholar (no date
limit performed on). Search terms included “ribavirin”, “ICN 1229”, “administration, inhaled" or
“inhalation”, “administration, oral” or “oral”, “respiratory syncytial virus”, “drug therapy”, “pneumonia”,
“respiratory tract infection”, “respiratory syncytial virus infections/drug therapy. Example search strategy
for Pubmed: Search strategy: [(ribavirin OR ICN 1229) AND (“administration, oral” OR “oral” OR
“administration, inhalation” OR “inhalation”)] AND (“respiratory tract infection” OR “pneumonia”)
Additional references were identified from records in the original search, the National Comprehensive
Cancer Network (NCCN) Guidelines, and the FDA database Drugs@FDA.

Inclusion/Exclusion Criteria

Inclusion criteria was based upon the PICOS method and records meeting all of the following criteria
were included in the qualitative analysis.10 Patient population was defined as immunocompromised
hospitalized adults ≥ 18 years old with HSCT or BMT, other malignancy, neutropenia (absolute
neutrophil count (ANC) ≤ 500 neutrophils/mL), SOT, HIV, chronic corticosteroid use defined as greater
than 10mg of prednisone or equivalent per day,11 or receipt of maintenance immunosuppressant(s).
Patients must also have a documented RSV infection of the lower respiratory tract or RSV pneumonia.
Intervention criteria included treatment with RBV AER alone or in combination with other therapies.
Studies were included whether or not comparison to oral or intravenous RBV or other drug therapies
occurred. To meet inclusion criteria, studies must have reported at least one of the following outcome
measures: in-hospital mortality, 30-day all-cause mortality, or RSV-mortality defined by autopsy, or
change in pulmonary function as defined in the manuscript. If specific mortality was not stated, it was
assumed to be in-hospital mortality. Post hoc, the decision was made to include the occurrence of
obstructive bronchiolitis (OB) or bronchiolitis obliterans syndrome (BOS) as an outcome in lung
transplant recipients. All observational studies and controlled trials, retrospective or prospective, meeting
all or any of the above criteria were included. Reviews and foreign language publications were excluded.
When outcomes were inseparable for mixed populations the study was excluded. For example, studies
reporting adult and pediatric population outcomes were excluded if the adult outcomes were not reported
separately. Other examples of mixed populations are mixed community acquired respiratory viruses (i.e.
parainfluenza virus), mixed upper and LRTI, and mixed ribavirin methods of administration.

Study selection and quality assessment
Search results were divided and reviewed independently by LA or CH and all records were reviewed by
KW. The authors first reviewed titles and abstracts. Records not immediately rejected were obtained in
full text and reviewed for inclusion criteria by LA or CH. A second determination of inclusion versus
exclusion was performed by KW. Adjudication was performed by the third author when necessary.
The only exception to this process was the handling of the Google Scholar search results. Due to the

high volume of citations returned, KW performed the initial determination independently and then LA
or CH performed the second determination. Selected studies were reviewed for quality based upon the
GRADE approach.12 Randomized clinical trials may begin with a high quality rating and observational
studies begin with a low quality rating. Quality levels are upgraded or downgraded based upon several
factors such as but not limited to design, precision or bias. Some trials may be down or upgraded for
multiple factors.
Data extraction and analysis
Data extraction was performed independently by CH (HSCT) and LA (all other populations) and verified
by KW. All relevant PICOS data, sample size, study time period, limitations, ribavirin dose and
frequency, duration of therapy, monotherapy versus combination therapy, timing of treatment (early
versus late), and mechanical ventilation (MV) was collected. Discrepancies or disagreements were
resolved through discussion amongst the authors.

Search results
A total of 1,787 records were identified. The Google Scholar search comprised 75% of the records
(1,350). The PRISMA flow diagram is located in Figure 1.10 This qualitative review includes 15
publications meeting inclusion criteria; thirteen identified in the original systematic search and 2
identified via the updated PubMed search.13-27 All of the trials are observational and begin with a low
quality rating. No trials meet criteria for upgrading to moderate or high quality, including the three
prospective trials.14,,22,25 No articles were identified that met the inclusion criteria for patients with HIV,
receiving chronic corticosteroids, or maintenance immunosuppressant therapies. Based on the lack of
randomized trials, lack of comparative groups, and heterogeneity of the study population a narrative
review was prepared.

Oncology HSCT/BMT patients

A total of 163 cases of RSV LRTI were reported in 8 articles (Table 1),13-20 published from 1995-2018, on
the use of RBV AER in oncology patients focusing on BMT/HSCT recipients. All articles were classified
as low or very low quality data. Numbers of patients who underwent allogeneic and autologous BMT or
HSCT are listed when available. Of the 163 cases, 125 received RBV AER, 3 received IVIG
monotherapy, and 32 received RBV PO. The most common reported dosage regimen included 2 grams
(g) inhaled over 2-3 hours (h) every 8 h (n=58), or 6g inhaled over 18 h every 24 h (n=23). Duration of
RBV AER therapy ranged from 1 to 30 days. A total of 85 patients received RBV AER in combination
with adjunctive therapy such as IVIG, IVIG (RSV-neutralizing antibodies), and /or PZB.13-19 Early
versus late treatment outcomes with mechanical ventilation was reported in 2 trials.13,14 Only one study
had comparative mortality data with RBV PO.20

Ghosh et al studied cases of RSV infections in autologous BMT/peripheral blood stem cell (PBSC) breast
cancer patients over an eight year period from 1992 to 2000.13 Of a population of 249 patients, only 6
developed RSV LRTI. Disease onset occurred less than 30 days from transplant in 5 patients and
between 30 and 100 days in one patient. A total of 5 of the 6 patients were in the pre-engraftment period
with all 6 patients having lymphocyte counts of ≤ 200 cells/mL. Engraftment was defined as the absence
of neutropenia for 3 days after conditioning therapy and transplantation. Patients were treated with a
combination of RBV AER and IVIG or RSV-IVIG for a mean of 12 days. Length of therapy was based
on the patients’ immunologic status, response, and duration of viral shedding. In-hospital mortality was
33% (2/6), with both patients who expired being in the pre-engraftment period. Initiation of combination
therapy occurred during the upper respiratory stage for one patient who progressed to pneumonia and
survived. The remaining 5 patients had therapy initiated at the pneumonia stage with 2 deaths. Mortality
in patients receiving RBV AER within 24 h of MV was 25% (1/4) compared to 100% (1/1) who received
therapy post MV.

Whimbey et al prospectively reviewed adult BMT patients hospitalized with RSV pneumonia or
tracheobronchitis over a 9 week period.14 Pneumonia was diagnosed in 16 patients, with 4 patients
progressing to pneumonia from tracheobronchitis.

Of the 16 patients, 6 patients were in the pre-

engraftment period and 4 were neutropenic. A total of 16 patients received combination therapy with
RBV AER and IVIG with RSV-neutralizing antibodies. Duration of therapy was determined by severity
of illness, clinical response, and engraftment status. Overall in-hospital mortality was 50% (8/16). Early
treatment, defined as RBV AER given greater than 1 day before MV, resulted in a mortality of 33%
(4/12) compared to 100% (4/4) who received treatment within one day of intubation. All 4 patients who
did not receive RBV AER expired. When stratified by type of transplant (autologous versus allogeneic),
neutropenia (< 1,000 neutrophils/mL), and engraftment status (resolution of neutropenia after transplant),
the author stated that mortality was not significantly influenced by these risk factors, although the number
of patients in this study is small.

McCoy et al retrospectively reviewed adult patients with hematologic malignancies or HSCT who were
diagnosed with RSV infections and received RBV AER with or without PZB treatment from 2006 to
2008.15 A guideline developed by their interdisciplinary antibiotic stewardship team recommended RSV
LRTI patients receive RBV AER for 3 days and one dose of PZB as soon as possible from diagnosis, then
reassess for continued RBV AER every 3 days. Of the 26 patients with RSV infection, 13 were
diagnosed with LRTI. Severe immunodeficiency was present in 7 of 13 patients with LRTI. This was
defined as HSCT ≤ 6 months from RSV diagnosis, leukopenia (white blood count ≤ 2 cells x 103/mm3, or
lymphopenia (lymphocytes ≤ 0.1 cells x 103/mm3 The 30-day mortality was 0% (0/13) in this
population.

Bourgouin et al retrospectively studied allogeneic transplant patients diagnosed with RSV from January
2000 to June 2012.16 Patients with neutropenia, pneumonia, or active graft versus host disease received

treatment with a standardized protocol of RBV AER for 5 days and IVIG for 4 days. The authors
presented the results of the first 32 patients in abstract form. Donor characteristics included 15 matched
sibling, 13 matched unrelated, and 4 mismatched donors. The median (interquartile range) day from
transplant to RSV infection was 382 (241-1049). Only 1 death occurred in 16 patients diagnosed with a
LRTI, with a reported case fatality rate of 6.3% (95% CI: 0.2 to 30.2%).

Mihelic et al performed a retrospective cohort study of BMT and leukemic patients from 2007 to 2013
infected with RSV who presented to a hospital with either a URTI or LRTI.17 A total of 60 patients were
hospitalized and 31 diagnosed with LRTI. The median (range) of ANC and acute lymphocyte count for
all infected patients was 1.6 (0-11) cells/mm3 and 0.8 (0-7.3) cells/mL respectively. Patients treated with
RBV AER and PZB had a 60 day mortality of 12.9% (4/31) and a RSV-mortality rate of 6.5%. The
authors mentioned that therapy was started early, but there was no details provided in the abstract.

McCarthy et al retrospectively reviewed all patients with an allogenic BMT and RSV disease over a 5
year period from 1993 to 1998.18 Patients were identified for review by virology reports, search of the
BMT database, and anecdotal reports. Of the 26 patients identified, only 4 were adult patients with LRTI.
A LRTI infection in this study was defined as positive chest signs and/or significant hypoxemia with
oxygenation saturation of less than 90% on room air. Only 1 of the 4 patients had a positive infiltrate on
chest radiograph. Of the 4 patients, 1 patient received RBV AER in combination with RBV IV and IVIG
and survived. The remaining 3 patients received IVIG monotherapy with 100% mortality, although none
reported as RSV related.

Peck et al performed an observational study that included all HSCT candidates who had positive RSV
surveillance testing prior to BMT.19

There were 37 pediatric and adult patients who were diagnosed

with RSV URTI prior to transplant. Of these patients, 3 adults were diagnosed after the start of
cyclophosphamide and total body irradiation conditioning regimen, and were transplanted. RSV

progressed to LRTI in 2 patients and both received RBV AER combination therapy. One patient died of
RSV pneumonia and the other survived the RSV infection, but died on day 90.

Foolad et al performed a retrospective cohort study on all HSCT patients with either an URTI or LRTI
who received greater than 48 hours of RBV AER or RBV PO from September 2014 to April 2017.20 Of
124 patients identified 72 patients received RBV at the LRTI stage. A total of 40 received RBV AER and
32 received RBV PO. Demographic data was not stratified by patients with LRTIs. The dosing regimen
of RBV AER was 2g over 3 hours q8h or RBV PO dosed at 600mg every q8h or 10mg/kg followed by
20mg/kg/day divided into 3 doses. There was no criteria reported for determination of RBV duration of
therapy. The duration of therapy for URTI and LRTI combined is a median (IQR) of 5 (4-5) and 5 (5-8)
for RBV AER and RBV PO respectively; separate data was not reported. In addition, patients did not
receive concomitant immunoglobulin therapy. There was no difference in 30-day mortality in patients
treated with RBV PO and RBV AER 4/29 (13.8%) and 6/39 (15.4%), p=1.0. The authors did not
comment on the 4 patients that were not included in the mortality analysis. Length of stay, transfer to the
intensive care unit, and mechanical ventilation was reported for both URTI and LRTI population, but was
not stratified to the LRTI population.

Other malignancy or neutropenic patients (ANC ≤ 500 neutrophils/mL)
A total 33 cases of RSV LRTI occurring in oncology/neutropenic patients who received RBV AER were
reported in 2 articles (Table 2) published in 1995 and 2014.21,22 The articles were classified as low or
very low quality. All participants had a diagnosis of leukemia and did not undergo a BMT/HSCT. Of the
33 cases, 22 received RBV AER and 11 were not treated. RBV AER dosing regimens varied from 2g
over 2 to 3 h every 8 h to 6g aerosolized over 18 h daily. Duration of RBV AER therapy ranged from 2 to
36 days. Combination therapy with IVIG was documented in 6 patients and 16 patients received either

monotherapy or combination therapy with IVIG or PZB. One article addressed early versus late treatment
outcomes in MV patients.22

Torres et al performed a retrospective cohort study of leukemic patients with evidence of RSV identified
by the microbiology laboratory.21 Of 52 patients identified, 45 were admitted to the hospital and 27
patients were diagnosed with a LRTI. Of those with a LRTI, 26% were admitted to the ICU, the median
APACHE II score was 16 (9-23), and the median length of hospital stay was 12 days. A total of 16
patients received RBV AER either as monotherapy or in combination with IVIG or PZB. RBV AER was
initiated a median of 1 day (1-12) from RSV diagnosis. The 30 day mortality rate was 6.3% (1/16)
compared to 36% (4/11) in the no treatment group (p=0.1).

Whimbey et al performed a prospective cohort study to determine outcomes of all adult leukemia patients
who were hospitalized with an acute respiratory illness and RSV was identified by culture.22 A total of 6
patients presented with LRTI, neutropenia and lymphopenia and received treatment with RBV AER in
combination with IVIG. The duration of therapy was individualized at the discretion of the prescriber,
based on illness severity, clinical response, and time to recovery from neutropenia. In-hospital mortality
was 83% (5/6). All 4 patients who were initiated on RBV AER within 24 h of mechanical ventilation
died. The sole survivor received early treatment when the FIO2 was 35% with a low supplemental
oxygen requirement.

Solid organ transplant recipients (SOT)
A total 65 cases of RSV LRTI were reported in 4 articles (Table 3)23-26, published from 1998-2012 in
adult SOT patients. One study included 36 immunocompromised patients with approximately 50% lung
transplant patients.27 All studies were classified as low or very low quality. Zamora et al was designed

with case match comparators which may increase its quality rating, but since it was published only as an
abstract, a full quality analysis could not be completed.25 The majority of patients were lung or heart-lung
recipients. Of the 101 cases, 76 were initiated on RBV AER and 23 on RBV PO. A single patient
received RBV AER with transition to RBV PO and 2 were not treated. RBV AER dosing regimens varied
from 2g every 8 h to 6g over 12 or 18 h daily. Duration of RBV AER therapy ranged from 3 to 30 days.
Early versus late treatment outcome was addressed in one study25 and 2 studies reported outcomes with
MV.23,24 BOS/OB was addressed in 3 studies.24,25,26

Ariza et al performed a retrospective cohort study of adult and pediatric SOT patients hospitalized with
RSV during 2007 to 2009.23 Of 263 cases, only 8 adult patients with RSV LRTI were identified.
Transplants included lung (n=2), kidney (n=2), kidney/pancreas (n=1), and liver (n=3). Lymphocyte
counts were ≤ 500 cells/mm3 in 6 of the 8 patients. The time from RSV diagnosis to the initiation of
either RBV AER or RBV PO was 4.1 days (range 2-5 days). In-hospital mortality occurred in 0 of 5 and 1
of 2 patients treated with RBV AER and RBV PO, respectively. The 1 death occurred in a patient
infected with RSV 21 days post lung transplant and was on MV for 212 days. The hospital length of stay
ranged from 11-30 days and 22-212 days in patients who received RBV AER and RBV PO. The author
also reported that RBV AER started after 4.5 compared to 2.5 days from diagnosis resulted in a trend of
increase hospital length of stay and prolonged viral shedding.

Palmer et al retrospectively evaluated lung transplant patients with community acquired viral infections
including adenovirus, RSV, influenza, or parainfluenza viruses from 1992 to 1997 and compared
outcomes to patients without viral infections.24 Of 10 patients with viral infections, 5 patients were
infected with RSV. All patients were within 24 months post-transplant. Of the 5 patients, 4 patients
received RBV AER with 1 death reported during hospitalization. MV was required in 2 patients with 1 of
the 2 patients surviving. There was no data on the timing of RBV AER in respect to MV. In addition, 2

of the 4 surviving patients developed OB. The diagnosis of OB was made pathologically or clinically if
there was a decline in spirometry > 15% of baseline without evidence of acute rejection or infection.

Zamora et al in a prospective case control study evaluated 30 day mortality and incidence of BOS in 44
lung transplant patients receiving RBV AER monotherapy or combination with PZB, RSV IVIG, or
IVIG.25 This study found a statistically significant lower 30 day mortality (0% vs 27%) and incidence of
BOS (21% vs 100%) in the early treatment group, defined as less than 2 weeks post symptom onset. This
was in abstract form and the patients treated greater than 2 weeks post symptom onset were not clearly
delineated.

Li et al performed a retrospective cohort of adult lung or heart/lung transplant patients from 2006 to 2010
with the primary outcome to compare the use of RBV AER and RBV PO on the incidence of BOS
progression in RSV infected patients.26 Included patients had to be at least 30 days from transplant and
were excluded if survival was less than 6 months. Treatment was determined by prescriber preference. A
total of 19 patients were included in the analysis; 12 patients with LRTI were treated with RBV AER (4
patients) or RBV PO (8 patients). Only 4 of the 8 patients treated with RBV PO were hospitalized.
Severe disease, defined as the need for MV, was present in 1 and 2 patients in the RBV AER and RBV
PO groups, respectively. Hospital and 30 day mortality was 0% (0/8). Hospital length of stay (including
URTI) with RBV AER and RBV PO was 11 ± 15.1 and 5 ± 1.5 days, respectively (p=0.37). The primary
outcome of BOS included both patients with upper and LRTI. Infection severity was defined by oxygen
requirement and was similar in both groups. A total of 3 of 15 patients who received RBV AER at
baseline had BOS 1 or greater at the time of infection and 2 patients progressed or developed new onset
BOS at 6 months follow up. There were no cases of BOS in the 6 patients who received RBV PO.

Trang et al performed a retrospective cohort study from 2013 to 2016 on adult patients who received
either RBV AER or RBV PO for the treatment of RSV infections in the outpatient or inpatient setting.27

Of 240 patients with RSV disease, only 36 patients had LRTI and were hospitalized. This cohort
consisted of patients with HCT, hematologic malignancy (non-transplant), lung/liver transplant, and
structural lung disease. A total of 19 and 17 patients were treated with RBV AER and RBV PO
respectively. There was no criteria for the duration of therapy. The median RBV duration for all patients
(URTI and LRTI) was 9 days in the RBV AER group and 10 days in the RBV PO group. Patients in the
HCT group may have also received concomitant treatment with IVIG. All cause 30-day mortality in the
LRTI cohort was 1 of 19 (5.3%) and 3 of 17 (17.6%) in the RSV AER and RSV PO group respectively.
There were 5 patients who required an increase in supplemental oxygen in the RBV AER group and 2
patients in the RBV PO group. None of the patients in either group required mechanical ventilation.

Adverse drug events
Documentation of ADEs were available in 5 of the 15 studies reviewed.14,22,23,26,27 ADEs related to RBV
AER included psychiatric manifestations (anxiety, depression, feeling of isolation; n = 14), wheezing (n =
4), bronchospasm (n=2) snowflakes/hail blowing in face (n = 6), and precipitation in ventilator tubing (n
= 5). There were 2 patients that developed anemia after receiving RBV PO, one requiring a blood
transfusion. One patient on RBV PO developed thrombocytopenia and a decrease in absolute lymphocyte
count. Nausea was reported in 6 patients, but did not state whether the patients were on RBV AER or
RBV PO.

Discussion
This systematic review was designed to review the outcomes in-hospital mortality and ADEs to help
practitioners decide whether to initiate RBV AER for treatment of RSV LRTI in hospitalized adult
immunocompromised patients. An extensive literature search revealed an absence of randomized clinical
trials to provide quality evidence. The reviewed trials span from 1987 to 2017 and utilize different dosing
regimens, durations, timing from diagnosis, and diagnostic methods to detect RSV disease. It was also
difficult to discern population data on patients with LRTI, since a majority of studies included data on

both URTI and LRTI. In this systematic review 4 trials present mortality as a function of timing of RBV
AER therapy and the authors report a mortality benefit.13,14,22,25 The efficacy of this treatment modality
appears to be decreased if the therapy is initiated after the start of MV. This may be related, to problems
with administration of RBV AER in patients on MV or severity of illness. Patient isolation and the
resulting psychological effects must be weighed against the benefit of therapy.

Currently, there are no published systematic reviews that evaluate the use of RBV AER for LRTI in the
adult immunocompromised population. A recent 2 year observational study reported a 30 day mortality
rate in HSCT/SOT, immunocompromised non-transplant patients, and chronic obstructive pulmonary
disease patients of 5.8%, 4.2%, and 10.3%.28 This study did not differentiate between URTI, LRTI, or
RBV route of administration. Shah et al published a review in HSCT patients with LRTI and reported a
RSV mortality of 24% in patients receiving RBV AER combination therapy.29 The definition of RSV
mortality was not based on autopsy results. It is difficult to compare mortality amongst the studies
reviewed since most studies contained less than 10 patients with LRTI treated with RBV AER. The 30day mortality in studies that contain more than 10 patients with HSCT, malignancy, and transplant range
from 0% to 15.4%, 6.3%, and 0% to 27% respectively. 15,16,17,20,21,25,27

The paucity of comparative data was evident in this review. Of the observational studies reviewed, only 3
studies compared RBV AER to RBV PO in the immunocompromised population.20,23,27 The ease of use
and decreased cost of RBV PO makes it an attractive therapeutic option, although there is very limited
data to show improved efficacy over RBV AER. A systematic review of RBV PO in non-influenza
respiratory viral infections reported a mortality ranging from 0-31% and 10-20% in both the HSCT and
the lung transplant population.30 A direct comparison cannot be made with RBV AER since the
population studied included both URTI and LRTI and the severity of illness varied amongst populations.

The time from diagnosis to the initiation of RBV AER varied widely. In the trials that presented mortality
data based on late initiation in relationship to diagnosis or mechanical ventilation the mortality rates were
27% (3/11) and 100% (9/9) respectively.13,14 Based on these results, prompt diagnosis of RSV LRTI and
initiation of RBV AER may improve outcomes. Nevertheless, there may be a time point when the use of
RBV AER may not be effective; including patients who develop respiratory failure and are intubated.
Some authors hypothesize that this may be due to a decrease in the amount of ribavirin able to penetrate
the lower lung during ventilation or possibly from the amount of ribavirin that coats the ventilator circuit
tubing.6

Only 5 studies commented on the occurrence of ADEs in patients receiving RBV AER.14,22,23,26,27 In
studies that reported ADE, the majority were psychiatric in nature. Drug administration via use of a face
mask inside a double-tent scavenger system for up to 18 h per day causes the patient to experience
prolonged isolation. Clinicians must consider the psychological effects of therapy including loneliness,
anxiety and depression. Wheezing and bronchospasm were documented in 6 patients, although it is
difficult to determine if the wheezing was a result of RSV LRTI or RBV AER effect on airway resistance.
Healthcare workers and patients should be educated on the potential teratogenic risks, as well as nasal,
pharyngeal, bronchial, and/or eye irritation during RBV AER exposure.31 Lastly, RBV AER led to
precipitation in the ventilator circuit in 5 events. It is important that respiratory policy and procedures are
in place before RBV AER therapy is administered. Respiratory therapists must be trained on the
appropriate administration technique, since it may vary with specific ventilator types.

Guidance for the treatment of RSV LRTI in adults is available from national and international
stakeholders including the Infectious Diseases Society of America (IDSA), whom do not recommend
antiviral therapy due to the lack of proven value.32 In 2013, the Fourth European Conference on
Infections in Leukemia (ECIL-4) guidelines were published and recommend treating RSV LRTI with
RBV AER [2g over 2 h every 8 h or 6g over 18 h per day for 7-10 days (BII recommendation)] plus IVIG

given previous studies suggesting improved outcomes. Oral RBV and intravenous RBV have weaker
quality of evidence and strengths of recommendation (BIII and CIII, respectively).33 The 2018 NCCN
Prevention and Treatment of Cancer-Related Infections guidelines (version 1.2019) recommend
considering RBV PO 600 to 800mg po twice daily or RBV AER 6g over 12 to 18 h daily or 2g over 2h 3
times daily for the treatment of RSV LRTI due to increased risk of mortality in the stem cell transplant or
leukemia patient population.34 Due to NCCN panel disagreement, this recommendation carries a
Category 3 level of evidence. It instructs the decision to use oral versus aerosolized ribavirin should be
individualized by institution.

This systematic review identifies the low quality of evidence that is available to guide therapeutic
decisions for treatment of RSV LRTI in hospitalized immunocompromised adults. Identified trends
suggest patients receiving more rapid treatment have improved outcomes. If patients and prescribers are
willing to accept the psychiatric and respiratory ADEs identified in this review, the last barrier is the
rising acquisition cost. Aerosolized RBV has been available since 1985 at an original cost of $229 USD
per day (6g vial).35 In 1994, the cost increased to over $1,000 USD AWP per day of therapy, and is
currently nearing $30,000 USD AWP daily.8,36 The introduction of the generic product and hospital
purchasing contracts may result in lower drug acquisition cost. These figures simply represent drug costs,
and do not include the indirect costs related to the isolation room, drug administration, and nursing and
respiratory therapist support. There are new antiviral agents being studied for RSV infection including
fusion inhibitors, nucleoside analogues and non-nucleoside polymerase inhibitors, but none are currently
FDA approved.37,38

Limitations
The limitations of this study are a result of the many limitations present in the included studies, including
small sample size, minimal patient demographics, limited information on duration of administered RBV
AER and administration of additional therapies that overall confounds the results. Although not

calculated due to the lack of studies with comparator groups, it is evident that there is heterogeneity
amongst the different trials and patient populations. It is also difficult to ascertain the cause of mortality in
this high risk population when there are other potential causes for mortality including concomitant
bacterial pathogens and underlying comorbidities. Some studies included in this systematic review were
performed in the 1980’s and the diagnosis of RSV was confirmed by viral culture, since then there have
been significant advances with rapid diagnostic testing for RSV disease that should improve time to
diagnosis and treatment. In addition, there was some variability in the definition of LRTI and pneumonia
in the studies.

Conclusion
There is a lack of comparative trials on the use of RBV AER for the treatment of RSV LRTI in adult
hospitalized immunocompromised patients. This systematic review only identified studies in the
HSCT/BMT, leukemic, and transplant population. Dosing regimens ranged from 2g over 2-3h every 8h
to 6g over 12-18h daily with no standardized durations. No conclusions can be made on the mortality
benefit with combination therapy (IVIG and or PZB).There may be a mortality benefit when RBV AER is
initiated early after the diagnosis or prior to MV, although this warrants further study. Patient isolation
and the resulting psychological effects must be weighed against the benefit of therapy.

Funding: No funding was supplied for this project.
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Table 1: RBV AER in hospitalized adult oncology patients (focus on HSCT/BMT recipients with RSV LRTI
Ref.

[13]

Type of Study

# of Patients with

Agent(s)

Time from diagnosis

Year

LRTI

Duration of therapy

to start of ribavirin

Retrospective

6

RBV AER 6g over 18 h every 24 h + IVIG

Early treatment:

Cohort

Breast cancer

500mg/kg every 48 h

initiated <24h before

patients

(n = 5)

MV

1992-2000

PBSC = 2
BMT = 4



initiated ≥24 h after

(RSV-neutralizing antibodies) 500mg/kg

MV

ADE

In-hospital mortality RBV AER:

NR

33% (2/6)


Late treatment:
RBV AER 6g over 18 h every 24 h + IVIG

Outcome(s)

30-d mortality RBV AER: 17%
(1/6)



Early vs late treatment outcomes
o

every 48 h

Mortality in patients receiving
early treatment: 20% (1/5)

o

(n = 1)

Mortality in patients receiving
late treatment: 100% (1/1)

Duration of therapy: mean: 12d
(7-17d)



Outcome based on days after BMT:
o

Pre-engraftment: 40%
(2/5)

o

Post-engraftment: 0%
(0/1)
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[14]

Prospective

19

RBV AER 6g over 18 h every 24 h + IVIG

Early treatment:

Surveillance study

BMT

(RSV-neutralizing antibodies) 500mg/kg

initiated > 1d before

every 48 h

intubation

(n = 16)

Late treatment:

Duration of therapy: mean: 11d

initiated within 1d of

(3-22d)

intubation

(cohort)
1/8/1993-3/4/1993



In-hospital mortality RBV AER :
56% (9/16)



Early vs late treatment outcomes
o

Mortality in patients receiving
early treatment: 22% (2/9)

o

o

Anxiety,
depression,
isolation and/or
loneliness
(n=12)

Mortality in patients receiving

Psychiatric

late treatment: 100% (7/7)

consultation

Early initiation was associated
with survival (p < 0.05)

(n=3)
Non-complaince
(n=3)

Snowflakes and
hail” blowing in
the face (n=4)

Psychiatric
consultation
(n=3),

Crystallization
in ventilation
tubing but no
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airway
obstruction
(n = NR)

[15]

Retrospective

13

RBV AER 6g over 12 h every 24 h x 3d +

Given as soon as

Cohort

HSCT/

PZB 15mg/kg IV over 1 h x 1 (n = 13)

possible

Lymphoma/Leuk

Duration of therapy: mean number of RBV

emia

AER doses: 5 +/- 2.1

2006-2008

[16]

Retrospective

16

RBV AER 2g every 8 h x 15 doses + IVIG

Cohort

Allo

500mg/kg/d x 4d (n = 16)

2000-2012

[17]

[18]

NR

30-d mortality RBV AER: 0%

NR

(0/13)



In-hospital mortality RBV AER:

NR

6.3% (1/16)

Duration of therapy: 5d

Retrospective

31

RBV AER (unknown dose) plus PZB

Cohort

BMT/

(unknown dose) (n = 31)

2007-2013

Leukemia

Retrospective

4

RBV AER 6g over 18 h every24 h + RBV IV

Within 24h

Cohort

Allo BMT

15mg/kg/d in 3 divided doses + IVIG (n=1)

(0-16d)

1993-1998



NR



RSV mortality RBV AER: 6.5%

NR

(2/31)



In-hospital mortality RBV AER 0%
(0/1)



In hospital mortality IVIG 100%
(3/3)

NR
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IVIG 0.2-0.4 g/kg/d 2 or 3 times weekly
(n=3)
Duration of therapy:
median 17d (8-30 d)

[19]

Retrospective

2

RBV AER 2g over 2 h every 8 h + IVIG

Cohort

Allo

(n=1, survivor)

1987-2000

NR



In-hospital/30–d mortality RBV

NR

AER: 50% (1/2)


RBV AER 2g daily x 4d then 2g over 2 h
every 8 h; received IVIG throughout RBV

Both cases infected during
conditioning period

AER therapy (n=1, nonsurvivor)
Duration: unknown

[20]

Retrospective

72

RBV AER 2g over 3 h every 8h (n=40)

Cohort

BMT

RBV PO 600mg every 8h or 10mg/kg

2014-2017

followed by 20mg/kg/d in 3 divided doses

NR



(6/39)


(n=32)
Duration of therapy: NR

30-d mortality RBV AER: 15.4%

30-d mortality RBV PO: 13.8%
(4/29) p=1.0



90-d mortality RBV AER: 30.8%
(12/39)



90-d mortality RBV PO: 17.2%
(5/29) p=0.263

LRTI: lower respiratory tract infection
RBV: ribavirin

NR for LRTI
population
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AER: aerosolized
IVIG: intravenous immunoglobulin
PBSC: peripheral blood stem cell
PZB: palivizumab
RSV: respiratory syncytial virus
BMT: bone marrow transplant
HSCT: hematopoietic stem cell transplantation
Allo: allogeneic
Auto: autologous
NR: not reported
MV: mechanical ventilation
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Table 2: RBV AER in hospitalized adult other malignancy or neutropenic patients (ANC ≤ 500 neutrophils/mL) with RSV LRTI
Ref.

Type of study

Number of

Agent(s)

Time from diagnosis to

participants with

Duration of therapy

start of RBV

Outcome(s)

ADE

LRTI

[21]

Retrospective

27

RBV AER 6g (20mg/ml) for 18 h every 24 h or 2g

median 1d

Cohort

AML/ALL

(60mg/L) over 2-3 h every 8 h

(1-12d)

2000-2005

ANC <500



(1/16)


neutrophil/mL

+/- IVIG 500mg/kg q48 h for duration of RBV

Lymphopenia

therapy

<1,000

+/- PZB 15 mg/kg x 1

lymphocytes/mL

n=16

Median duration 7d (2 – 14d)

No treatment n=11

30-d mortality RBV AER: 6.3%

30-d mortality No treatment:
36% (4/11)



P=0.1

NR
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[22]

Prospective

6

RBV AER 20mg/mL 18 h by face mask or

NR

Cohort

AML, ALL, CML

endotracheal tube

1993-1994

ANC < 500

+ IVIG 500mg/kg q48h for duration of RBV AER

Late therapy: within 24

neutrophils/mL

treatment

h of MV

Lymphopenic

(mean 19d range 9-36d)





In-hospital mortality RBV AER

Precipitation of

combination therapy: 83% (5/6)

RBV therapy in

RSV mortality RBV AER: 67%

respiratory tubing

(2/3)


<200

MV mortality RBV AER late
therapy: 100% (4/4)



lymphocytes/mL
LOT individualized based on severity, clinical
response and time to recovery from neutropenia



(n=4)

1 – patient who died was

Non-intubated
patients

noncompliant with treatment

complaining of

50% of the time

snowflakes and

1 – Survivor had low oxygen

hail blowing in

requirement when treatment was

face (n=2)

started FIO2 35%
Anxiety (NR)

Loneliness due to
confinement from
treatment (NR)

Psychologically
unable to tolerate
(n=1)
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Wheezing (n=4)
Responded to
bronchodilators
and patients also
had wheezing
before therapy

RBV: ribavirin
AER: aerosolized
IVIG: intravenous immunoglobulin
RSV: respiratory syncytial virus
LRTI: lower respiratory tract infection
MV: mechanical ventilation
LOT: length of therapy
CML: chronic myelogenous leukemia
AML: acute myeloid leukemia
ALL: acute lymphoblastic leukemia
NR: not reported
PZB: palivizumab
ANC: absolute neutrophil count
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FIO2: fraction of inspired oxygen

Table 3: Aerosolized ribavirin in hospitalized adult solid organ transplant recipients with RSV LRTI

Ref.

Type of study

Number of

Agent(s)

Time from

participants with

Duration of therapy

diagnosis to

LRTI

[23]

Retrospective

8

Cohort

Lung 2

2007-2009

Kidney 2

ADEs

start of RBV

RBV AER 6g over 18 h x 30d (n=1)

RBV AER 6g over 18 h x 10d, PZB (n=2)

Kidney/Pancreas 1
Liver 3

Outcome(s)

4.1d (range 2-



In-hospital mortality RBV AER: 0% (0/5)

AER: no adverse

5d)



In-hospital mortality RBV PO: 50% (1/2)

events encountered



In-hospital mortality no treatment: 0% (0/1)



In-hospital mortality RBV AER combination

RBV AER 6g over 18 h + PZB, IVIG x unknown
duration (n=1)

therapy: 0% (0/4)


In-hospital mortality RBV AER monotherapy: 0%
(0/1)

PO: hemolytic anemia
n=1
(occurred in patient
who initially received
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RBV AER 6g over 18 h x 7d, RBV 400mg PO



MV mortality RBV PO: 50% (1/2)

every 8 h x 4d (n=1)



MV mortality no treatment: 0% (0/1)

RBV AER) required
transfusion

Outcome based on days after transplant
RBV PO x 5d (n=1)

RBV PO, PZB, IVIG x 5d (n=1)



≤ 365d: mortality: 1/5



> 365d: mortality: 0/3

Organ Rejection: 0% (0/8)
Length of Stay RBV AER: 11 to 30 d

(RBV PO dose ranged from 300mg every 12 h to
600mg every 8 h)

No therapy (n=1)

[24]

Retrospective

5

RBV AER n=4

Cohort

Single Lung 4

No treatment n=1

1992-1997

Bilateral Lung
transplant 1

NR



In-hospital mortality RBV AER: 25% (1/ 4)



MV mortality RBV AER 50% (1/2)



Outcome based on days post-transplant


≤ 365d RBV AER: mortality: 50% (1/2)



> 365d: RBV AER mortality: (0/2)

OB – RBV AER: 50% (2/4) mean follow up 758d

NR
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Prospective

44

Group A

Case control

Lung Transplant

RBV AER 2g TID x 5d + MP 10mg/kg/d x 3d, +



30-d mortality 0% (0/33)

RSV IVIG 500mg/kg x 1 dose OR PZB 15mg/kg



BOS 21% (7/33) onset 11.1 ± 8 months

2004

NR

Group A

x 1 dose + IVIG 500mg/kg x 1 dose
n=33

Group B

Group B


30-d mortality 27% (3/11)



BOS 100% (8/8) p <0.05 Onset 6.8 ± 4 months

RBV AER 2g TID x 5d + MP 10mg/kg/d x 3d or
group A therapy started > 2 weeks after

Group C

symptom onset



30-d mortality = 0% (0/33)

n=11



BOS = 15% (5/33) onset 14.1 ± 6 months

Group C
Controls (not infected with RSV)
(case matched for indication for lung transplant
and time from lung transplant)
n=33

NR
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Retrospective

8

RBV AER 6g over 12h x 3-5d

Cohort

Lung or Heart Lung

± IVIG, MP (10 – 15 mg/kg/d) n=8

2006-2010

Transplant

NR



In-hospital/ 30-d mortality RBV AER: 0% (0/8)



In-hospital/30-d mortality RBV PO: 0% (0/4)



Length of stay(included URTI and ambulatory

RBV 400mg PO TID x 5-10d



events encountered

PO: anemia (within 2

pts)

± IVIG, MP (10-15mg/kg/d) n=4

AER: no adverse



RBV AER 5± 1.5 days



RBV PO 11 ± 15.1 days

weeks (1)

BOS (included URTI and ambulatory pts)


RBV AER: 3 pts baseline BOS 1 or
greater at time of infection, 2 pts had
new onset or progression of BOS at 6
months



[27]

Retrospective

19

RBV AER 6g over 6h q day

Cohort

Lung transplant

2013-2016

50% of population

RBV PO 800mg PO BID if weight ≥ 75kg or

of RBV AER

600mg PO BID if weight <75kg

NR

RBV PO: no BOS reported



30-d mortality RBV AER 5,3% (1/19)

Nausea n=6 (not



30-d mortality RBV PO 17.6% (3/17)

reported if RBV PO or



No patients required MV

RBV AER)

Bronchospasm n=2
17

Hematologic malignancy and HSCT patients

Lung transplant

IVIG 500 mg/kg IV 3 times weekly x 2 weeks

45% of population

was given at the discretion of treating physician

of RBV PO

(RBV AER)

Thrombocytopenia/
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decrease absolute
lymphocyte count n=1
RBV PO

RBV: ribavirin
AER: aerosolized
IVIG: intravenous immunoglobulin
RSV: respiratory syncytial virus
LRTI: lower respiratory tract infection
MV: mechanical ventilation
PZB: palivizumab
PO: oral
MP: methylprednisolone
BOS: bronchial obliterans syndrome
NR: not reported
OB: obstructive bronchiolitis
RSV IVIG: IVIG with RSV-neutralizing antibodies
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